Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05050461 | Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma(LYMPHO-CoVac) | terminated | N/A | 120 | Versailles HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | terminated | Phase 1 | 7 | Nicholas ButowskiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.(MAPtivate-6) | terminated | Phase 1 / Phase 2 | 40 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial(VEnT) | terminated | Phase 2 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01851395 | Rapid Autopsy and Procurement of Cancer Tissue | terminated | — | 32 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT02908048 | Extracellular RNA Markers of Liver Disease and Cancer | terminated | — | 1,865 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia | terminated | Phase 2 | 21 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT04370522 | Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer(NIKOLE) | terminated | — | 32 | Spanish Breast Cancer Research GroupOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05091866 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | terminated | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05812274 | Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients | terminated | N/A | 30 | Columbia UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | terminated | Phase 1 | 68 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | terminated | N/A | 101 | University Hospital, RouenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | terminated | Phase 4 | 141 | TakedaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03738553 | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy | terminated | — | 13 | University of WashingtonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05815160 | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | terminated | Phase 1 | 34 | Debiopharm International SAINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT06192004 | Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD(LOOP) | terminated | — | 83 | AstraZenecaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04631744 | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04639024 | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | terminated | Phase 2 | 3 | Gwynn Long, M.D.OTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05755269 | Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women | terminated | — | 19 | Mayo ClinicOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05718882 | Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC | terminated | N/A | 5 | RenJi HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06456411 | Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer | terminated | N/A | 106 | Roswell Park Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02706652 | Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients | terminated | — | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04261777 | Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients | terminated | Phase 3 | 172 | Saving Patients' Lives Medical B.V.INDUSTRY | 4 | Apr 28, 2026 | clinicaltrials |
| NCT06125028 | [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma(LYMFOR) | terminated | Phase 3 | 8 | Pentixapharm AGINDUSTRY | 5 | Apr 28, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06897579 | Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer | terminated | Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05268003 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | terminated | Phase 2 | 4 | University of WashingtonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | terminated | Phase 2 | 13 | Partner Therapeutics, Inc.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06235242 | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer | terminated | N/A | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06513663 | Exercise as Maintenance Therapy in Advanced Lung Cancer | terminated | N/A | 2 | Indiana UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06519669 | Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer | terminated | N/A | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03622775 | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | terminated | Phase 1 / Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05090566 | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | terminated | Phase 2 | 46 | PfizerINDUSTRY | 2 | Apr 24, 2026 | clinicaltrials |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | terminated | Phase 2 | 3 | Emory UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT01472445 | Vitamin D and Breast Cancer: Does Weight Make a Difference? | terminated | Phase 2 | 41 | Melinda TelliOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02562625 | Trial of Pembrolizumab and Radiotherapy in Melanoma(PERM) | terminated | Phase 2 | 17 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03334305 | Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas(ACTION) | terminated | Phase 1 | 18 | University of FloridaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04435691 | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04984343 | Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer(FORT) | terminated | Phase 2 | 33 | Weill Medical College of Cornell UniversityOTHER | 2 | Apr 23, 2026 | clinicaltrials |
| NCT05341349 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | terminated | — | 57 | Pediatric Brain Tumor ConsortiumNETWORK | 2 | Apr 23, 2026 | clinicaltrials |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma | terminated | Phase 1 | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | terminated | Phase 1 | 8 | PfizerINDUSTRY | 2 | Apr 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2026source: clinicaltrials